Prognostic Model of HCV-related Disease Progression After DAAs
Prognostic Model of HCV-related Disease Progression After DAAs
In this study, the investigator would conduct an ambispective cohort study to build a
 prediction model of HCV-related disease after DAAs.
The emergence of direct antiviral agents (DAAs) makes it possible to cure HCV, and the
 sustained virological response (SVR) rate is up to 90% after DAAs therapy. However, the
 acquisition of SVR does not mean the cure of HCV-related diseases, some patients still
 developed liver cirrhosis, liver cancer and other diseases after achived SVR by DAAs
 therapy.In this study the investigator would like to bulid a prediction model of HCV-related
 disease after DAAs by conducting an ambispective cohort study. The participants of this study
 would be adult patients (≥18 years old) with chronic HCV infection and have received DAA
 therapy, the investigator would retrospectively collected DAA therapy-related information,
 and follow-up all the enrolled participants every 6 months to observe their liver-related
 disease outcomes (composite liver outcome, including liver-related deaths, hepatocellular
 carcinoma, liver decompensation, and liver transplantation).
Inclusion Criteria:

 -  adult patients (≥18 years old) with chronic HCV infection that were HCV RNA positive;

 -  have received DAA treatment;

 -  would like to adhere to the follow-up

 Exclusion Criteria:

 -  lack of HCV treatment information;